Latest On Verrica Pharmaceuticals Inc (VRCA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-09 19:33 EST | News | Verrica Pharmaceuticals GAAP EPS of -$0.15 beats by $0.05, revenue of $0.03M misses by $0.61M | N/A |  |
| 2023-03-06 20:34 EST | News | Verrica Pharmaceuticals GAAP EPS of -$0.14 beats by $0.06, revenue of $0.07M | N/A | |
| 2023-02-13 12:29 EST | News | Verrica rises as RBC upgrades citing “regulatory catalyst” for lead asset | N/A | |
| 2023-01-24 08:21 EST | News | Verrica refiles seeking FDA approval of viral skin disease drug VP-102 | N/A | |
| 2022-11-08 02:16 EST | News | Verrica Pharmaceuticals GAAP EPS of $0.00 beats by $0.14, revenue of $8.3M beats by $4.05M | N/A | |
About Verrica Pharmaceuticals Inc (VRCA):
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.
General
- Name Verrica Pharmaceuticals Inc
- Symbol VRCA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- IPO Date2018-06-15
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.verrica.com
Valuation
- Price/Book (Most Recent Quarter) 9.05
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.77
- Next Year EPS Estimate -$1.74
- Next Quarter EPS Estimate -$0.43
- Return on Assets -35%
- Return on Equity -87%
- Earnings Per Share -$1.12
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 423.68 million
- EBITDA -30030000
- PE Ratio -1.15
- Analyst Target Price $20.83
- Book Value Per Share $1.32
Share Statistics
- Shares Outstanding 25.87 million
- Shares Float 8.84 million
- % Held by Insiders 4885%
- % Held by Institutions 34.68%
- Shares Short 1.48 million
- Shares Short Prior Month 1.47 million
- Short Ratio 18.57
- Short % of Float 12%
- Short % of Shares Outstanding 6%
Technicals
- Beta 2.35
- 52 Week High $18.42
- 52 Week Low $6.02
- 50 Day Moving Average 14.57
- 200 Day Moving Average 10.77
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Verrica Pharmaceuticals Inc (VRCA) Dividend Calendar:
Verrica Pharmaceuticals Inc (VRCA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Verrica Pharmaceuticals Inc (VRCA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Verrica Pharmaceuticals Inc (VRCA) Chart:
Verrica Pharmaceuticals Inc (VRCA) News:
Below you will find a list of latest news for Verrica Pharmaceuticals Inc (VRCA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Verrica Pharmaceuticals Inc (VRCA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest VRCA Trades:
Verrica Pharmaceuticals Inc (VRCA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-08 | 8-K (Current report) | |
| 2020-08-26 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-05 | 8-K (Current report) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-23 | 8-K (Current report) | |
| 2020-07-14 | 8-K (Current report) | |
| 2020-06-29 | 8-K (Current report) | |
| 2020-06-29 | 8-K (Current report) | |
| 2020-06-12 | 4 (Statement of changes in beneficial ownership of securities) | |
Verrica Pharmaceuticals Inc (VRCA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Verrica Pharmaceuticals Inc (VRCA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4885%
Institutional Ownership: 3468%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-25 | Craig Ballaron | Director | Buy | 4,772.00 | 8.57 | 40,896.04 | 10,000.00 | |
| 2020-08-24 | Craig Ballaron | Director | Buy | 5,228.00 | 9.16 | 47,888.48 | 5,228.00 | |
| 2020-08-20 | Paul B Manning | Director | Buy | 20,000.00 | 9.09 | 181,800.00 | 8,099,394.00 | |
| 2020-08-18 | Paul B Manning | Director | Buy | 10,000.00 | 8.55 | 85,500.00 | 1,481,719.00 | |
| 2020-08-17 | Paul B Manning | Director | Buy | 6,000.00 | 6.92 | 41,520.00 | 1,471,719.00 | |
| 2020-08-14 | Paul B Manning | Director | Buy | 50,000.00 | 6.51 | 325,500.00 | 1,465,719.00 | |
| 2020-08-14 | Sean Stalfort | Director | Buy | 15,700.00 | 6.38 | 100,166.00 | 462,110.00 | |
| 2020-08-13 | Paul B Manning | Director | Buy | 108,500.00 | 6.41 | 695,485.00 | 1,415,719.00 | |
| 2020-08-13 | Ted White | President and CEO | Buy | 10,661.00 | 6.28 | 66,951.08 | 17,966.00 | |
| 2020-08-13 | Sean Stalfort | Director | Buy | 15,550.00 | 6.45 | 100,297.50 | 446,410.00 | |
| 2020-08-13 | A BRIAN DAVIS | Chief Financial Officer | Buy | 7,900.00 | 6.24 | 49,296.00 | 7,900.00 | |
| 2019-10-10 | Paul B Manning | Director | Buy | 6,900.00 | 15.05 | 103,845.00 | 8,079,394.00 | |
| 2019-10-09 | Paul B Manning | Director | Buy | 8,778.00 | 14.06 | 123,418.68 | 8,072,494.00 | |
| 2019-10-08 | Paul B Manning | Director | Buy | 5,208.00 | 14.02 | 73,016.16 | 8,063,716.00 | |
| 2019-09-09 | Matt Davidson | 10% Share Holder | Sell | 6,300.00 | 10.82 | 68,166.00 | 2,556,179.00 | |
| 2019-09-06 | Matt Davidson | 10% Share Holder | Sell | 1,400.00 | 12.07 | 16,898.00 | 2,562,479.00 | |
| 2019-09-06 | Matt Davidson | 10% Share Holder | Sell | 4,712.00 | 11.44 | 53,905.28 | 2,563,879.00 | |
| 2019-09-06 | Matt Davidson | 10% Share Holder | Sell | 3,802.00 | 10.38 | 39,464.76 | 2,568,591.00 | |
| 2019-09-05 | Matt Davidson | 10% Share Holder | Sell | 3,100.00 | 10.29 | 31,899.00 | 2,572,393.00 | |
| 2019-08-29 | Matt Davidson | 10% Share Holder | Sell | 2,188.00 | 10.14 | 22,186.32 | 2,575,493.00 | |